GB1841
GB1841 is an orally active and selective galectin inhibitor with human galectin-1 Kd of 0.027 μM, human galectin-3 Kd of 0.14 μM, mouse galectin-1 Kd of 0.034 μM and mouse galectin-3 Kd of 1.170 μM. GB1841 can be used for the research of lung cancer.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- CAS No.: 2573135-33-6
- 화학식: C18H16BrClN6O4S2
- 분자량:559.84
-
보관:
Please store the product under the recommended conditions in the Certificate of Analysis.
All Galectin Isoforms
More
Biological Activity
제품 설명
IC50 & Target
[1]|
Galectin-1 0.027 μM (Kd) |
Galectin-3 0.14 μM (Kd) |
In Vitro
GB1841 potently binds human galectin-1 (Kd 0.027 μM), human galectin-3 (Kd 0.14 μM), and human galectin-4C (Kd 0.25 μM); it also [1].
GB1841 potently binds mouse galectin-1 (Kd 0.034 μM) and mouse galectin-3 (Kd 1.170 μM)[1].
GB1841 reduces A549 human lung adenocarcinoma cell viability by 62% at 90 μM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. .
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6 (female, 17−19 g, syngeneic implantation of LL/2 lung cancer cells)[1]
-
Dosage:30 mg/kg
-
Administration:p.o.; b.i.d. for 3 days
-
Result:Achieved free plasma Cmax levels of 1 μM.
Remained above the mouse galectin-1 Kd (0.034 μM) for over 24 h.
Did not reach levels above the mouse galectin-3 Kd (1.170 μM).
Demonstrated a >90-fold therapeutic window compared to cell toxicity levels (62% viability reduction at 90 μM in A549 cells).
Chemical Information
-
CAS No. 2573135-33-6
-
분자량 559.84
-
화학식 C18H16BrClN6O4S2
-
SMILES
O[C@@H]1[C@H](N2C=C(C3=NC(Cl)=CS3)N=N2)[C@@H](OC)[C@@H](SC4=C(C#N)N=CC(Br)=C4)O[C@@H]1CO
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
순도&문서
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)